A Novel Off-the-Shelf TCR Bispecific Platform for Cancer Immunotherapy
Time: 2:20 pm
day: Conference Day One
Details:
• Plug and play approach for making TCR engagers integrated with our clinical validated TCE technology
• Our approach was optimized from different design for best activity and IgG-like manufacturing properties
• The platform was validated by testing several TCR targets in vitro and in vivo with potent preclinical activity
